Polymer of methyl malonic acid suppress inflammation by downregulating IL-2 through ROS overproduction

preprint OA: closed
Full text JSON View at publisher

Abstract

Metabolites belonging to the propionate metabolism pathway can regulate immune cell responses in the context of autoimmunity and chronic inflammation. Methyl malonic acid (MMA), a metabolite in this pathway is known to cause dysregulation of T cell oxidative phosphorylation (OXPHOS) and downregulating pro inflammatory T cell effector functions. However, the effects of MMA on T cell signaling and T cell activation is not clearly known. Furthermore, since MMA is a small molecule, using it in the context of therapy remains a problem. It gets metabolized in a short time and millimolar concentrations are required to get effective results. This work describes a novel polymer, 1,6 MMA, synthesized using 1,6 Hexane-diol and MMA, which helps in slow, steady and continuous release of the small molecule. Doses in micromolar ranges generate long lasting and robust immunosuppression of activated T cells via an IL2 dependent mechanism in both human and mice T cells without causing non-specific toxicity. This causes a dysregulated expression of pSTAT5 which eventually enhances BLIMP1 mediated T cell apoptosis. Finally, 1,6 MMA mediated T cell suppression is caused due to increase in mitochondrial ROS production. Extrapolation of our findings in-vivo showed the polymer inhibited autoreactive T cell responses in mice with collagen induced arthritis (CIA). Overall, 1,6 MMA, a novel metabolite polymer, has major therapeutic potential in combating inflammatory disorders.
Full text 1,562 characters · extracted from oa-doi-fallback · click to expand
Abstract Metabolites belonging to the propionate metabolism pathway can regulate immune cell responses in the context of autoimmunity and chronic inflammation. Methyl malonic acid (MMA), a metabolite in this pathway is known to cause dysregulation of T cell oxidative phosphorylation (OXPHOS) and downregulating pro inflammatory T cell effector functions. However, the effects of MMA on T cell signaling and T cell activation is not clearly known. Furthermore, since MMA is a small molecule, using it in the context of therapy remains a problem. It gets metabolized in a short time and millimolar concentrations are required to get effective results. This work describes a novel polymer, 1,6 MMA, synthesized using 1,6 Hexane-diol and MMA, which helps in slow, steady and continuous release of the small molecule. Doses in micromolar ranges generate long lasting and robust immunosuppression of activated T cells via an IL2 dependent mechanism in both human and mice T cells without causing non-specific toxicity. This causes a dysregulated expression of pSTAT5 which eventually enhances BLIMP1 mediated T cell apoptosis. Finally, 1,6 MMA mediated T cell suppression is caused due to increase in mitochondrial ROS production. Extrapolation of our findings in-vivo showed the polymer inhibited autoreactive T cell responses in mice with collagen induced arthritis (CIA). Overall, 1,6 MMA, a novel metabolite polymer, has major therapeutic potential in combating inflammatory disorders. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00